An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, demonstrating ...
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...
Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylamâs RNAi therapeutic platform, function upstream of todayâs medicines by potently silencing messenger RNA ...
The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...
Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback